Drug class

Antiparkinsonian Amantadine Formulations

"Antiparkinsonian Amantadine Formulations" is not a formal FDA Established Pharmacologic Class, but rather a clinical and formulary categorization designating oral delivery systems of amantadine—including immediate-release and extended-release capsules and tablets—indicated for neurologic movement disorders. Read more about Antiparkinsonian Amantadine Formulations

27 drugs in this class 25 manufacturers

Advertisement

Drugs in Antiparkinsonian Amantadine Formulations

Showing 10–18 of 27 drugs

Filter & compare in the drug finder → Opens the drug finder with Antiparkinsonian Amantadine Formulations preselected. Add indication or manufacturer filters there.

About Antiparkinsonian Amantadine Formulations.

"Antiparkinsonian Amantadine Formulations" is not a formal FDA Established Pharmacologic Class, but rather a clinical and formulary categorization designating oral delivery systems of amantadine—including immediate-release and extended-release capsules and tablets—indicated for neurologic movement disorders.

Therapeutic activity is primarily mediated through weak, uncompetitive N-methyl-D-aspartate receptor antagonism and modulation of central dopaminergic transmission.

Formulations in this category are utilized in the management of idiopathic Parkinson disease, post-encephalitic or drug-induced extrapyramidal symptoms, and levodopa-induced dyskinesia or motor fluctuations.